Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
HIV Medicine|June 17, 2026
Comparison of four frailty scores to predict adverse health events and mortality in people living with HIV aged 70 years and more (ANRS EP 66 SEPTAVIH study)Clotilde Allavena, Diane Abulizi, Hubert Blain, et al.
JAMA|April 14, 2011
Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trialOdile Launay, Diane van der Vliet, Arielle R Rosenberg, et al.
Antiviral Therapy|April 9, 2008
Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113)Laurence Slama, Emilie Lanoy, Marc-Antoine Valantin, et al.
AIDS Research and Human Retroviruses|November 13, 2008
Short communication: Long-term persistence of vaccine-induced HIV seropositivity among healthy volunteersBenjamin Silbermann, Michel Tod, Corinne Desaint, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 5, 2014
Care of hepatitis C virus infection in France: modifications in three consecutive surveys between 1995 and 2010Guillaume Geri, Marianne Maynard, Eric Rosenthal, et al.
Journal of Medical Virology|October 2, 2012
Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1Jade Ghosn, Laurence Slama, Aziza Chermak, et al.
Antiviral Therapy|February 5, 2008
A 6-month interruption of antiretroviral therapy improves adipose tissue function in HIV-infected patients: the ANRS EP29 Lipostop StudyMin Ji Kim, Pascale Leclercq, Emilie Lanoy, et al.
The Journal of Antimicrobial Chemotherapy|October 7, 2022
Impact on renal function of daily and on-demand HIV pre-exposure prophylaxis in the ANRS-PREVENIR studyGeoffroy Liegeon, Lambert Assoumou, Jade Ghosn, et al.
The Journal of Antimicrobial Chemotherapy|April 13, 2016
Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial)Laurence Slama, Roland Landman, Lambert Assoumou, et al.
Journal of Virology|July 28, 2012
HIV controllers maintain a population of highly efficient Th1 effector cells in contrast to patients treated in the long termBenoît Vingert, Daniela Benati, Olivier Lambotte, et al.
Pageof 6